Simultaneous determination of elbasvir and grazoprevir in their pharmaceutical formulation by synchronous fluorescence spectroscopy coupled to dual wavelength method

Attia, Khalid A.M.; El‐Olemy, Ahmed; Ramzy, Sherif; Hasan, M. A.; Abdel-Kareem, Rady F.

doi:10.1016/j.saa.2020.119157

Cited by 19 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 37 ] It also can be used to quantitatively determine several medicines in a single run due to its small, precise, and sharp spectrum. [ 36 , 38 , 39 , 40 , 41 ]…”

Section: Introductionmentioning

confidence: 99%

“…[37] It also can be used to quantitatively determine several medicines in a single run due to its small, precise, and sharp spectrum. [36,[38][39][40][41] To date, no method for the simultaneous quantification of FPV and HCQ as co-administered drugs in biological fluids has been documented. This necessitates the establishment of a responsive F I G U R E 1 Chemical structure of (a) favipiravir and (b) hydroxychloroquine sulphate procedure for simultaneous estimation of both drugs for their therapeutic drug monitoring.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Quantitative analysis of favipiravir and hydroxychloroquine as FDA‐approved drugs for treatment of COVID‐19 using synchronous spectrofluorimetry: application to pharmaceutical formulations and biological fluids

et al. 2022

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID‐19) is a contagious viral infection caused by coronavirus 2 (SARS‐CoV‐2) that causes severe acute respiratory syndrome. It has ravaged several countries and burdened many healthcare systems. As the process of authorizing a novel treatment for human use is extensive and involves multiple phases to obtain safety information and identify potential concerns. Therefore, the fastest and easiest choice was to use United States Food and Drug Administration (US FDA)‐approved drugs such as favipiravir and hydroxychloroquine. For the simultaneous estimation of both medications, a simple synchronous spectrofluorimetric approach was established in which both drugs were measured at 372 and 323 nm, respectively in the presence of each other without interference at Δλ 60 nm. The effect of various experimental conditions on synchronous fluorescence intensities were thoroughly investigated and optimized. The maximum synchronous fluorescence intensities were obtained at pH 5.4 using acetate buffer (0.2 M, 0.5 ml) and ethanol as a diluent. Excellent linearity ranges were obtained using 1.0–18.0 ng/ml and 10.0–120.0 ng/ml for favipiravir and hydroxychloroquine, respectively. The approach exhibited high sensitivity with detection limits down to 0.25 ng/ml and 1.52 ng/ml and quantitation limits down to 0.77 ng/ml and 4.62 ng/ml, respectively. Spiking human plasma samples with the studied drugs yielded high % recoveries, allowing a significant bioanalytical application. Moreover, the method was validated according to International Conference on Harmonization guidelines and further applied to commercial pharmaceutical preparations with good results.

show abstract

“…[ 37 ] It also can be used to quantitatively determine several medicines in a single run due to its small, precise, and sharp spectrum. [ 36 , 38 , 39 , 40 , 41 ]…”

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

Quantitative analysis of favipiravir and hydroxychloroquine as FDA‐approved drugs for treatment of COVID‐19 using synchronous spectrofluorimetry: application to pharmaceutical formulations and biological fluids

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In addition, the mathematical derivation of the synchronous spectra can help in spectral resolution of multi-components in different mixtures. Previous reports have described the use of synchronous fluorescence spectroscopy scanning for the determination of drugs in mixtures in different matrices, including pharmaceutical form or plasma matrix [12] , [13] , [14] . [12] , [13] , [14] .…”

Section: Introductionmentioning

confidence: 99%

“…Previous reports have described the use of synchronous fluorescence spectroscopy scanning for the determination of drugs in mixtures in different matrices, including pharmaceutical form or plasma matrix [12] , [13] , [14] . [12] , [13] , [14] .…”

Section: Introductionmentioning

confidence: 99%

Green fitted second derivative synchronous spectrofluorometric method for simultaneous determination of remdesivir and apixaban at Nano gram scale in the spiked human plasma

Batubara

Abdelazim

Gamal

et al. 2023

Spectrochimica Acta Part A: Molecular and Biomolecular Spectros

Self Cite

View full text Add to dashboard Cite

“…Fluorescence spectrometry is an important analytical tool for drug quantification due to its high sensitivity and low cost [1]. However, its application for simultaneous and direct quantification of mixtures of multiple drugs is limited due to spectral overlap problems [2,3]. These overlap problems could be solved by applying the synchronous fluorescence detection mode, in which both excitation and emission monochromators are scanned simultaneously, resulting in simplification and narrowing of spectral bands.…”

Section: Introductionmentioning

confidence: 99%

Application of green first derivative synchronous spectrofluorometric method for quantitative analysis of fexofenadine hydrochloride and pseudoephedrine hydrochloride in pharmaceutical preparation and spiked human plasma

2022

Self Cite

View full text Add to dashboard Cite

Fexofenadine hydrochloride and pseudoephedrine hydrochloride are prescribed in a combined dosage form for the treatment of allergic rhinitis. In the present work, a sensitive synchronous fluorescence spectroscopic method was applied in conjunction with first derivative for quantitative estimation of fexofenadine hydrochloride and pseudoephedrine hydrochloride in pure form, pharmaceutical tablets and spiked human plasma. Fexofenadine hydrochloride showed its conventional emission spectrum at 294 nm when excited at 267 nm. On the other hand, pseudoephedrine hydrochloride showed its conventional emission spectra at 286 nm when excited at 261 nm. The fluorescence intensities were greatly enhanced by the use of sodium dodecyl sulphate as a micellar surfactant. Application of the synchronous mode to measure the fluorescence spectra of the above drugs provided sharp narrowing bands, but the overlap was not completely resolved. Derivatization of the synchronous spectra to the first order completely resolved the overlap of the fluorescence spectra and allowed simultaneous quantitative determination of the drugs under study. Fexofenadine hydrochloride and pseudoephedrine hydrochloride could be determined from their first-order synchronous spectra at 286 and 294 nm, respectively, without interfering with each other. The method showed linearity with an excellent correlation coefficient in the concentration range of 100–1500 ng/mL for Fexofenadine hydrochloride and 50–1000 ng/mL for pseudoephedrine hydrochloride. The method was successfully applied for the simultaneous determination of the studied drugs in pharmaceutical formulation, with mean percent recoveries for Fexofenadine hydrochloride and pseudoephedrine hydrochloride of 99.49 ± 0.931 and 98.67 ± 0.634, respectively, and in spiked human plasma, with mean percent recoveries for Fexofenadine hydrochloride and pseudoephedrine hydrochloride of 95.21 ± 1.938 and 94.89 ± 1.763, respectively. Furthermore, the greenness of the described method was assessed using four different tools namely, the national environmental method index, the analytical eco-scale, the green analytical procedure index and the AGREE evaluation method. The proposed method seemed to be superior to the reported HPLC method with respect to the metrics of the greenness characters.

show abstract

Simultaneous determination of elbasvir and grazoprevir in their pharmaceutical formulation by synchronous fluorescence spectroscopy coupled to dual wavelength method

Cited by 19 publications

References 17 publications

Quantitative analysis of favipiravir and hydroxychloroquine as FDA‐approved drugs for treatment of COVID‐19 using synchronous spectrofluorimetry: application to pharmaceutical formulations and biological fluids

Quantitative analysis of favipiravir and hydroxychloroquine as FDA‐approved drugs for treatment of COVID‐19 using synchronous spectrofluorimetry: application to pharmaceutical formulations and biological fluids

Green fitted second derivative synchronous spectrofluorometric method for simultaneous determination of remdesivir and apixaban at Nano gram scale in the spiked human plasma

Application of green first derivative synchronous spectrofluorometric method for quantitative analysis of fexofenadine hydrochloride and pseudoephedrine hydrochloride in pharmaceutical preparation and spiked human plasma

Contact Info

Product

Resources

About